Nextgen Biomed Ltd
Simbolis: NXGN.TA
TLV
101.8
ILARinkos kaina šiandien
-106.3909
P/E santykis
0.0000
PEG koeficientas
7.56M
MRK kapitalizacija
- 0.00%
DIV pajamingumas
Nextgen Biomed Ltd (NXGN-TA) Finansinės ataskaitos
Balansas
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 0 | 5.2 | 12 | 5.7 | |||||||||
balance-sheet.row.short-term-investments | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.net-receivables | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.inventory | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.other-current-assets | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.total-current-assets | 0 | 5.3 | 12.3 | 5.9 | |||||||||
balance-sheet.row.property-plant-equipment-net | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.intangible-assets | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 1.6 | 7.3 | 0 | |||||||||
balance-sheet.row.long-term-investments | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.tax-assets | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.other-non-current-assets | 0 | 8.1 | 4.1 | 2.4 | |||||||||
balance-sheet.row.total-non-current-assets | 0 | 9.6 | 11.4 | 2.4 | |||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.total-assets | 0 | 14.9 | 23.6 | 8.3 | |||||||||
balance-sheet.row.account-payables | 0 | 0.2 | 0.1 | 0.1 | |||||||||
balance-sheet.row.short-term-debt | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.long-term-debt-total | 0 | 0 | 0 | 0 | |||||||||
Deferred Revenue Non Current | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | |||||||||
balance-sheet.row.other-current-liab | 0 | 1.1 | 0.6 | 1.4 | |||||||||
balance-sheet.row.total-non-current-liabilities | 0 | 1.4 | 2.1 | 0 | |||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.capital-lease-obligations | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.total-liab | 0 | 2.6 | 2.9 | 1.5 | |||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.common-stock | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.retained-earnings | 0 | -51.9 | -43.3 | -40.7 | |||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.other-total-stockholders-equity | 0 | 64.2 | 64.1 | 47.7 | |||||||||
balance-sheet.row.total-stockholders-equity | 0 | 12.4 | 20.8 | 7 | |||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 0 | 14.9 | 23.6 | 8.3 | |||||||||
balance-sheet.row.minority-interest | 0 | -0.1 | -0.1 | -0.1 | |||||||||
balance-sheet.row.total-equity | 0 | 12.3 | 20.7 | 6.9 | |||||||||
balance-sheet.row.total-liabilities-and-total-equity | 0 | - | - | - | |||||||||
Total Investments | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.total-debt | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.net-debt | 0 | -5.2 | -12 | -5.7 |
Pinigų srautų ataskaita
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0 | -8.6 | -2.5 | -1.3 | ||||||||||
cash-flows.row.depreciation-and-amortization | 0 | 0 | 0 | 0 | ||||||||||
cash-flows.row.deferred-income-tax | 0 | 5 | -0.1 | 0 | ||||||||||
cash-flows.row.stock-based-compensation | 0 | 0.2 | 0.2 | 0 | ||||||||||
cash-flows.row.change-in-working-capital | 0 | 0.7 | 0 | -0.2 | ||||||||||
cash-flows.row.account-receivables | 0 | 0 | 0 | 0 | ||||||||||
cash-flows.row.inventory | 0 | 0 | 0 | 0 | ||||||||||
cash-flows.row.account-payables | 0 | 0 | 0 | 0 | ||||||||||
cash-flows.row.other-working-capital | 0 | 0 | 0 | 0 | ||||||||||
cash-flows.row.other-non-cash-items | 0 | 0 | -0.1 | 0 | ||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 0 | 0 | 0 | 0 | ||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | 0 | -0.5 | 0 | ||||||||||
cash-flows.row.acquisitions-net | 0 | 0 | 0 | -0.5 | ||||||||||
cash-flows.row.purchases-of-investments | 0 | 0 | 0 | 0 | ||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 0 | 0 | 0 | ||||||||||
cash-flows.row.other-investing-activites | 0 | 0 | -2 | -1.9 | ||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | -4 | -2.5 | -2.4 | ||||||||||
cash-flows.row.debt-repayment | 0 | 0 | 0 | 0 | ||||||||||
cash-flows.row.common-stock-issued | 0 | 0 | 11.4 | 7 | ||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | ||||||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | ||||||||||
cash-flows.row.other-financing-activites | 0 | 0 | 0 | 0.7 | ||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | 0 | 11.4 | 7.7 | ||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 0 | 0 | 0 | ||||||||||
cash-flows.row.net-change-in-cash | 0 | -6.7 | 6.3 | 3.8 | ||||||||||
cash-flows.row.cash-at-end-of-period | 0 | 5.2 | 11.9 | 5.7 | ||||||||||
cash-flows.row.cash-at-beginning-of-period | 0 | 12 | 5.7 | 1.9 | ||||||||||
cash-flows.row.operating-cash-flow | 0 | -2.8 | -2.7 | -1.5 | ||||||||||
cash-flows.row.capital-expenditure | 0 | 0 | -0.5 | 0 | ||||||||||
cash-flows.row.free-cash-flow | 0 | -2.8 | -3.2 | -1.5 |
Pajamų ataskaitos eilutė
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 0 | 0 | 0 | ||||||||||
income-statement-row.row.cost-of-revenue | 0 | 0 | 0 | 0 | ||||||||||
income-statement-row.row.gross-profit | 0 | 0 | 0 | 0 | ||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||||
income-statement-row.row.research-development | 0 | - | - | - | ||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | ||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||
income-statement-row.row.other-expenses | 0 | -5 | 0 | 0 | ||||||||||
income-statement-row.row.operating-expenses | 0 | 3.6 | 2.8 | 1.3 | ||||||||||
income-statement-row.row.cost-and-expenses | 0 | 3.6 | 2.8 | 1.3 | ||||||||||
income-statement-row.row.interest-income | 0 | 0 | 0.3 | 0 | ||||||||||
income-statement-row.row.interest-expense | 0 | 0.1 | 0 | 0 | ||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||
income-statement-row.row.total-other-income-expensenet | 0 | 0.7 | 0.3 | 0 | ||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||||
income-statement-row.row.other-operating-expenses | 0 | -5 | 0 | 0 | ||||||||||
income-statement-row.row.total-operating-expenses | 0 | 0.7 | 0.3 | 0 | ||||||||||
income-statement-row.row.interest-expense | 0 | 0.1 | 0 | 0 | ||||||||||
income-statement-row.row.depreciation-and-amortization | 0 | 0 | 0 | 0 | ||||||||||
income-statement-row.row.ebitda-caps | 0 | - | - | - | ||||||||||
income-statement-row.row.operating-income | 0 | -9.3 | -2.8 | -1.3 | ||||||||||
income-statement-row.row.income-before-tax | 0 | -8.6 | -2.6 | -1.3 | ||||||||||
income-statement-row.row.income-tax-expense | 0 | 0.8 | 0.3 | 0 | ||||||||||
income-statement-row.row.net-income | 0 | -8.6 | -2.5 | -1.3 |
Dažnai užduodami klausimai
Kas yra Nextgen Biomed Ltd (NXGN.TA) bendras turtas?
Nextgen Biomed Ltd (NXGN.TA) bendras turtas yra 14888000.000.
Kokios yra įmonės metinės pajamos?
Metinės pajamos yra N/A.
Kokia yra įmonės pelno marža?
Įmonės pelno marža yra 0.000.
Koks yra įmonės laisvųjų pinigų srautas?
Laisvųjų pinigų srautas yra -0.200.
Kokia yra įmonės grynojo pelno marža?
Grynojo pelno marža yra 0.000.
Kokios yra bendros įmonės pajamos?
Bendrosios pajamos yra 0.000.
Kas yra Nextgen Biomed Ltd (NXGN.TA) grynasis pelnas (grynosios pajamos)?
Grynasis pelnas (grynosios pajamos) yra -8572000.000.
Kokia yra bendra įmonės skola?
Bendra skola yra 0.000.
Koks yra veiklos sąnaudų skaičius?
Veiklos sąnaudos yra 3581000.000.
Koks yra įmonės grynųjų pinigų skaičius?
Įmonės grynieji pinigai yra 0.000.